Provectus Biopharmaceuticals

OverviewSuggest Edit

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. Provectus is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.

TypePublic
Founded2002
HQKnoxville, US
Websiteprovectusbio.com

Latest Updates

Employees (est.) (Dec 2018)2

Key People/Management at Provectus Biopharmaceuticals

Tim Scott

Tim Scott

President
Eric Wachter

Eric Wachter

Chief Technology Officer
John Glass

John Glass

Interim CFO
Bruce Horowitz

Bruce Horowitz

Chief Operations Consultant
Show more

Provectus Biopharmaceuticals Office Locations

Provectus Biopharmaceuticals has an office in Knoxville
Knoxville, US (HQ)
7327 Oak Ridge Hwy
Show all (1)

Provectus Biopharmaceuticals Financials and Metrics

Provectus Biopharmaceuticals Revenue

USD

Net income (FY, 2018)

(8.2m)

Market capitalization (9-Oct-2018)

20.2m

Cash (31-Dec-2018)

51.0k

EV

27.2m
Provectus Biopharmaceuticals's current market capitalization is $20.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

8.8m11.0m13.3m16.0m5.5m3.3m

R&D expense

3.6m5.1m10.7m8.5m8.2m4.7m

Operating expense total

12.4m16.1m24.0m24.5m13.7m(8.1m)

Interest expense

969.7k
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

2.2m3.0m2.3m2.2m2.4m2.9m6.1m3.0m3.3m2.5m924.1k728.9k962.7k1.3m

R&D expense

1.3m1.0m1.4m2.3m2.1m2.7m2.4m2.0m2.5m1.9m2.4m2.4m1.9m987.2k

Operating expense total

3.5m4.0m3.7m4.5m4.4m5.6m8.5m5.0m5.8m4.4m3.3m3.1m2.9m5.2m

Net Income

(4.6m)(643.4k)(3.7m)(4.5m)(4.5m)(5.8m)(8.5m)(5.0m)(5.9m)(4.4m)(3.3m)(3.1m)(2.9m)(1.5m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

15.7m17.4m14.2m1.2m105.5k51.0k

Accounts Receivable

8.9m

Current Assets

19.1m14.7m1.8m958.3k1.0m

Total Assets

20.0m26.2m20.4m5.6m3.4m2.0m
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

8.3m18.1m17.8m14.2m23.1m18.9m9.8m4.9m5.2m437.0k1.1m208.3k244.1k130.6k

Current Assets

8.3m18.1m17.8m15.9m24.5m19.9m10.4m5.4m5.4m887.5k1.5m533.7k744.8k1.4m

Total Assets

12.8m22.1m21.6m22.8m31.2m26.6m16.0m10.8m10.7m4.5m4.9m3.9m3.1m3.5m

Accounts Payable

202.5k478.2k518.5k972.7k3.3m3.6m3.7m3.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(27.7m)(10.2m)(24.5m)(24.4m)(13.5m)(8.2m)

Depreciation and Amortization

6.4k8.5k13.2k13.1k15.9k14.1k

Accounts Payable

105.4k91.8k1.4m32.7k

Cash From Operating Activities

(9.9m)(13.8m)(17.4m)(21.9m)(10.3m)(5.2m)
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(11.1m)(643.4k)(11.1m)(4.5m)(9.1m)(14.9m)(8.5m)(5.0m)(5.9m)(4.4m)(7.7m)(10.8m)(2.9m)(4.4m)

Depreciation and Amortization

4.7k5.1k6.4k9.7k9.4k12.5k3.5k7.0k

Accounts Payable

(41.0k)129.3k77.8k532.0k

Cash From Operating Activities

(7.7m)(9.7m)(8.2m)(12.4m)(5.6m)(7.9m)(1.7m)(3.5m)
USDY, 2018

EV/CFO

-5.2 x

Financial Leverage

-0.1 x
Show all financial metrics

Provectus Biopharmaceuticals News and Updates

University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur

KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam College of Business (HCB) at the University of Tennessee, Knoxville as HCB’s 2018 Outstanding Entrepreneur…

Provectus Biopharmaceuticals Frequently Asked Questions

  • When was Provectus Biopharmaceuticals founded?

    Provectus Biopharmaceuticals was founded in 2002.

  • Who are Provectus Biopharmaceuticals key executives?

    Provectus Biopharmaceuticals's key executives are Tim Scott, Eric Wachter and John Glass.

  • How many employees does Provectus Biopharmaceuticals have?

    Provectus Biopharmaceuticals has 2 employees.

  • Who are Provectus Biopharmaceuticals competitors?

    Competitors of Provectus Biopharmaceuticals include Ohr Pharmaceutical, La Jolla Pharmaceutical Company and Onconova Therapeutics.

  • Where is Provectus Biopharmaceuticals headquarters?

    Provectus Biopharmaceuticals headquarters is located at 7327 Oak Ridge Hwy, Knoxville.

  • Where are Provectus Biopharmaceuticals offices?

    Provectus Biopharmaceuticals has an office in Knoxville.

  • How many offices does Provectus Biopharmaceuticals have?

    Provectus Biopharmaceuticals has 1 office.